First Horizon Advisors Inc. Sells 192 Shares of Catalent, Inc. (NYSE:CTLT)

First Horizon Advisors Inc. decreased its position in Catalent, Inc. (NYSE:CTLT) by 30.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 445 shares of the company’s stock after selling 192 shares during the quarter. First Horizon Advisors Inc.’s holdings in Catalent were worth $27,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in Catalent by 1.7% during the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after acquiring an additional 185 shares during the period. GAMMA Investing LLC boosted its stake in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in Catalent by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after buying an additional 220 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in Catalent by 2.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after buying an additional 229 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Catalent by 3.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock worth $432,000 after buying an additional 278 shares during the last quarter.

Catalent Price Performance

Catalent stock opened at $61.24 on Tuesday. The business’s fifty day moving average is $59.81 and its two-hundred day moving average is $58.32. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm has a market cap of $11.12 billion, a P/E ratio of -27.10, a P/E/G ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a 52 week low of $36.74 and a 52 week high of $61.50.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the company earned ($0.10) EPS. The firm’s revenue was up 4.2% compared to the same quarter last year. Equities research analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CTLT has been the topic of several research analyst reports. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to MarketBeat.com, Catalent currently has an average rating of “Hold” and a consensus price target of $63.40.

Insider Activity at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last quarter. Corporate insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.